Co-Diagnostics, Inc. (CODX)
| Market Cap | 6.65M -45.1% |
| Revenue (ttm) | 622,489 -84.1% |
| Net Income | -46.90M |
| EPS | -35.25 |
| Shares Out | 3.60M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 166,832 |
| Open | 1.900 |
| Previous Close | 1.900 |
| Day's Range | 1.805 - 1.950 |
| 52-Week Range | 1.350 - 46.500 |
| Beta | 1.26 |
| Analysts | Buy |
| Price Target | 90.00 (+4,778.05%) |
| Earnings Date | May 14, 2026 |
About CODX
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In... [Read more]
Financial Performance
In 2025, Co-Diagnostics's revenue was $622,489, a decrease of -84.10% compared to the previous year's $3.92 million. Losses were -$46.90 million, 24.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for CODX stock is "Buy." The 12-month stock price target is $90.0, which is an increase of 4,778.05% from the latest price.
News
Co-Diagnostics’ joint venture with CoMira finalizes facility lease agreement
Co-Diagnostics (CODX) announced that its joint venture, CoMira Diagnostics, has finalized a lease agreement for its planned manufacturing facility in Sudair Industrial City in the Kingdom of Saudi Ara...
Co-Diagnostics Joint Venture CoMira Finalizes Lease Agreement for Manufacturing Facility in Saudi Arabia's Sudair Industrial City
Lease execution highlights transition from approval to development and advances localized manufacturing strategy in the Kingdom of Saudi Arabia in accordance with Vision 2030 SALT LAKE CITY, May 8, 20...
Co-Diagnostics Announces First Quarter 2026 Earnings Release Date and Webcast
SALT LAKE CITY, April 30, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of m...
Co-Diagnostics Invited to Present at Stop TB Partnership Summit in Washington, D.C.
MTB test on Co-Dx PCR platform* to be presented at roundtable with Stop TB Partnership, U.S. Department of State, and global stakeholders SALT LAKE CITY, April 16, 2026 /PRNewswire/ -- Co-Diagnostics,...
Co-Diagnostics to Showcase Co-Dx PCR Platform and CE-IVD Solutions at ESCMID 2026 in Munich, Germany
Company to engage with global customers and distributors while expanding international commercial relationships SALT LAKE CITY, April 14, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (t...
Co-Diagnostics Executives to Participate in European Trade Mission with Utah Governor and WTC Utah
Trade mission itinerary of business, government, and industry briefings across Switzerland and Germany to include site visits to Roche Diagnostics, UBS, Zurich Innovation Park and more SALT LAKE CITY,...
Co-Diagnostics Earnings Call Transcript: Q4 2025
Revenue declined sharply year-over-year due to lower grant income, while operating expenses rose from a non-cash impairment. Strategic expansion in India and MENA, regulatory progress, and AI innovation position the business for future growth.
Co-Diagnostics Reports Full Year 2025 Financial Results
Advancing Global Commercialization Strategy Through CoSara and CoMira Joint Ventures Progressing Clinical Pipeline and Regulatory Pathways for PCR Platform Strengthening Technology Leadership with AI ...
Co-Diagnostics Ships Diagnostic Materials to India for Initiation of Tuberculosis Clinical Studies Following Recently Issued Guidance from the World Health Organization
The near-term commencement of clinical studies is expected to align with recent WHO tuberculosis recommendations for near-point-of-care molecular testing and utilizing tongue swab samples New recommen...
Co-Diagnostics to expand commercial, distribution territory across South Asia
Co-Diagnostics (CODX) has signed an agreement for CoSara Diagnostics, the Indian joint venture between Co-Dx and Ambalal Sarabhai Enterprises, to significantly expand its commercial and distribution t...
Co-Diagnostics Signs Agreement to Significantly Expand Commercial and Distribution Territory Across South Asia
Expansion into Bangladesh, Pakistan, Nepal, and Sri Lanka increases TAM in region to $13 billion and supports commercialization strategy for the PCR Pro ® and SARAGENE ® product line SALT LAKE CITY, M...
Co-Diagnostics Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Webcast
SALT LAKE CITY, March 17, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of m...
Co-Diagnostics to Present at Medical Korea 2026
Co-Dx to join WTC Utah and other Utah legislative and industry delegates March 19-22 in Seoul, South Korea SALT LAKE CITY, March 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" o...
Co-Diagnostics Receives Japanese Patent Covering Co-Dx PCR Platform Technologies
SALT LAKE CITY, March 12, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of m...
Co-Diagnostics Regains Compliance with Nasdaq Listing Requirements
SALT LAKE CITY, March 10, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of m...
Co-Diagnostics to Showcase PCR Platform at World Health Expo Labs Dubai
SALT LAKE CITY, Feb. 9, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (OTC: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecu...
Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture and Sell CoSara PCR Pro™ Instrument
CDSCO license on Form MD-5 authorizes CoSara to manufacture PCR Pro instrument in its Ranoli, India facility for sale or distribution SALT LAKE CITY, Feb. 5, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. ...
Co-Diagnostics JV, CoSara, Receives ISO 13485 Certification in Preparation for Manufacturing Upcoming PCR Platform
Company and CoSara believe that ISO certification is a critical component of the regulatory requirements for clearance of new platform SALT LAKE CITY, Feb. 4, 2026 /PRNewswire/ -- Co-Diagnostics, Inc....
Co-Diagnostics cut to Hold at Maxim on Nasdaq delisting
As previously reported, Maxim analyst Jason McCarthy downgraded Co-Diagnostics (CODX) to Hold from Buy. The company received written notice from NASDAQ that it had decided to delist the company’s stoc...
Co-Diagnostics downgraded to Hold from Buy at Maxim
Maxim downgraded Co-Diagnostics (CODX) to Hold from Buy.
Co-Diagnostics trading resumes
12:29 EST Co-Diagnostics (CODX) trading resumes
Co-Diagnostics trading halted, volatility trading pause
12:24 EST Co-Diagnostics (CODX) trading halted, volatility trading pause
Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships
SALT LAKE CITY, Jan. 12, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of m...
Co-Diagnostics trading halted, news pending
19:50 EST Co-Diagnostics (CODX) trading halted, news pending
Co-Diagnostics announces 1-for-30 reverse stock split
Co-Diagnostics (CODX) announced that it has filed a Certificate of Amendment to its Certificate of Incorporation to effect a reverse stock split of its common stock at a ratio of…